Targeted therapies of the LKB1/AMPK pathway for the treatment of insulin resistance

Future Medicinal Chemistry

Volumn 2, Issue 12, 2010, Pages 1785-1796

  Yamada, Eijiro ^a   Lee, Ting Wen A ^b   Pessin, Jeffrey E ^a   Bastie, Claire C ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b CHILDREN S HOSPITAL AT MONTEFIORE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 2 OXO 3 (4,5,6,7 TETRAHYDRO 1H INDOL 2 YLMETHYLENE) 1H INDOLE 5 SULFONIC ACID DIMETHYLAMIDE; 5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; FATTY ACID; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN SENSITIZING AGENT; LIVER KINASE B1; METFORMIN; PROTEIN KINASE FYN; ROSIGLITAZONE; UNCLASSIFIED DRUG;

DRUG TARGETING; ENZYME ACTIVITY; FATTY ACID METABOLISM; FOOD INTAKE; GLUCOSE METABOLISM; HUMAN; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DISCOVERY; HUMANS; INSULIN RESISTANCE; LIVER; METABOLIC DISEASES; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION;

EID: 78650217374     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.264     Document Type: Review

References (123)

1. Aschner P. Metabolic syndrome as a risk factor for diabetes. Expert Rev. Cardiovasc. Ther. 8, 407-412 (2010).
2. Kirby M, Yu DM, O'Connor S, Gorrell MD. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin. Sci. (Lond). 118, 31-41 (2009).
3. D'Alessio DA, Denney AM, Hermiller LM et al. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with Type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 81-88 (2009).
4. Fryer LG, Parbu-Patel A, Carling D. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J. Biol. Chem. 277, 25226-25232 (2002).
5. Woods A, Munday MR, Scott J, Yang X, Carlson M, Carling D. Yeast SNF1 is functionally related to mammalian AMP-activated protein kinase and regulates acetyl-CoA carboxylase in vivo. J. Biol. Chem. 269, 19509-19515 (1994).
6. Stapleton D, Gao G, Michell BJ et al. Mammalian 5'-AMP-activated protein kinase non-catalytic subunits are homologs of proteins that interact with yeast Snf1 protein kinase. J. Biol. Chem. 269, 29343-29346 (1994).
7. Polge C, Thomas M. SNF1/AMPK/SnRK1 kinases, global regulators at the heart of energy control? Trends Plant Sci. 12.20-28 (2007).
8. Hardie DG. AMPK: A key regulator of energy balance in the single cell and the whole organism. Int. J. Obes. (Lond). 32(Suppl. 4) S7-12 (2008).
9. Viollet B, Athea Y, Mounier R et al. AMPK: Lessons from transgenic and knockout animals. Front Biosci. 14, 19-44 (2009).
10. Steinberg GR, Kemp BE. AMPK in health and disease. Physiol. Rev. 89, 1025-1078 (2009). nn Review on AMPK structure, functions and activation.
11. Woods A, Cheung PC, Smith FC et al. Characterization of AMP-activated protein kinase b and gamma subunits. Assembly of the heterotrimeric complex in vitro. J. Biol. Chem. 271, 10282-10290 (1996).
12. Salt I, Celler JW, Hawley SA, Prescott A, Woods A, Carling D, Hardie DG. AMP-activated protein kinase: Greater AMP dependence, and preferential nuclear localization, of complexes containing the α2 isoform. Biochem. J. 334(Pt 1), 177-187 (1998).
13. Kodiha M, Rassi JG, Brown CM, Stochaj U. Localization of AMP kinase is regulated by stress, cell density and signaling through the MEK→ERK1/2 pathway. Am. J. Physiol. Cell. Physiol. 293, C1427-1436 (2007).
14. Suzuki A, Okamoto S, Lee S, Saito K, Shiuchi T, Minokoshi Y. Leptin stimulates fatty acid oxidation and peroxisome proliferator-activated receptor a gene expression in mouse C2C12 myoblasts by changing the subcellular localization of the α2 form of AMP-activated protein kinase. Mol. Cell Biol. 27, 4317-4327 (2007).
15. Warden SM, Richardson C, O'Donnell J Jr, Stapleton D, Kemp BE, Witters LA. Post-translational modifications of the b-1 subunit of AMP-activated protein kinase affect enzyme activity and cellular localization. Biochem. J. 354, 275-283 (2001).
16. Stapleton D, Mitchelhill KI, Gao G et al. Mammalian AMP-activated protein kinase subfamily. J. Biol. Chem. 271, 611-614 (1996).
17. Verhoeven AJ, Woods A, Brennan CH et al. The AMP-activated protein kinase gene is highly expressed in rat skeletal muscle. Alternative splicing and tissue distribution of the mRNA. Eur. J. Biochem. 228, 236-243 (1995).
18. Thornton C, Snowden MA, Carling D. Identification of a novel AMP-activated protein kinase b subunit isoform that is highly expressed in skeletal muscle. J. Biol. Chem. 273, 12443-12450 (1998).
19. Chen Z, Heierhorst J, Mann RJ et al. Expression of the AMP-activated protein kinase b1 and b2 subunits in skeletal muscle. FEBS Lett. 460, 343-348 (1999).
20. Woods A, Azzout-Marniche D, Foretz M et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol. Cell Biol. 20, 6704-6711 (2000).
21. Salt IP, Johnson G, Ashcroft SJ, Hardie DG. AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic b cells, and may regulate insulin release. Biochem. J. 335(Pt 3), 533-539 (1998).
22. Hardie DG. The AMP-activated protein kinase pathway - new players upstream and downstream. J. Cell Sci. 117, 5479-5487 (2004).
23. Hardie DG, Hawley SA, Scott JW. AMP-activated protein kinase - development of the energy sensor concept. J. Physiol. 574, 7-15 (2006).
24. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T, Neumann D. Dissecting the role of 5'-AMP for allosteric stimulation, activation and deactivation of AMP-activated protein kinase. J. Biol. Chem. 281, 32207-32216 (2006).
25. Stein SC, Woods A, Jones NA, Davison MD, Carling D. The regulation of AMP-activated protein kinase by phosphorylation. Biochem. J. 345(Pt 3), 437-443 (2000).
26. Musi N. AMP-activated protein kinase and Type 2 diabetes. Curr. Med. Chem. 13, 583-589 (2006).
27. Rafaeloff-Phail R, Ding L, Conner L et al. Biochemical regulation of mammalian AMP-activated protein kinase activity by NAD and NADH. J. Biol. Chem. 279, 52934-52939 (2004).
28. 2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J. Biol. Chem. 280, 29060-29066 (2005).
29. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1 activates Snf1 protein kinase in yeast and phosphorylates AMPactivated protein kinase in vitro. J. Biol. Chem. 281, 25336-25343 (2006).
30. Xie M, Zhang D, Dyck JR et al. A pivotal role for endogenous TGF-β-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. Proc. Natl Acad. Sci. USA 103, 17378-17383 (2006).
31. Hawley SA, Pan DA, Mustard KJ et al. Calmodulin-dependent protein kinase kinase-b is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2, 9-19 (2005).
32. Hawley SA, Boudeau J, Reid JL et al. Complexes between the LKB1 tumor suppressor, STRAD α/β and MO25 α/β are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2, 28 (2003).
33. Shaw RJ, Kosmatka M, Bardeesy N et al. The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl Acad. Sci. USA 101, 3329-3335 (2004).
34. Jensen TE, Rose AJ, Jorgensen SB et al. Possible CaMKK-dependent regulation of AMPK phosphorylation and glucose uptake at the onset of mild tetanic skeletal muscle contraction. Am. J. Physiol. Endocrinol. Metab. 292, E1308-1317 (2007).
35. 2+/calmodulin- dependent protein kinase kinase β. J. Biol. Chem. 273, 31880-31889 (1998).
36. Alessi DR, Sakamoto K, Bayascas JR. LKB1-dependent signaling pathways. Annu. Rev. Biochem. 75, 137-163 (2006). nn Complete review on liver kinase B1 (LKB1) structure and functions.
37. Sakamoto K, Goransson O, Hardie DG, Alessi DR. Activity of LKB1 and AMPKrelated kinases in skeletal muscle: Effects of contraction, phenformin and AICAR. Am. J. Physiol. Endocrinol. Metab. 287, E310-E317 (2004).
38. Sakamoto K, McCarthy A, Smith D et al. Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J. 24, 1810-1820 (2005).
39. Hemminki A, Tomlinson I, Markie D et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. Nat. Genet. 15, 87-90 (1997).
40. Jenne DE, Reimann H, Nezu J et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat. Genet. 18, 38-43 (1998).
41. Baas AF, Boudeau J, Sapkota GP et al. Activation of the tumour suppressor kinase LKB1 by the STE20-like pseudokinase STRAD. EMBO J. 22, 3062-3072 (2003).
42. Sapkota GP, Kieloch A, Lizcano JM et al. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth. J. Biol. Chem. 276, 19469-19482 (2001).
43. Collins SP, Reoma JL, Gamm DM, Uhler MD. LKB1, a novel serine/threonine protein kinase and potential tumour suppressor, is phosphorylated by cAMP-dependent protein kinase (PKA) and prenylated in vivo. Biochem. J. 345(Pt 3), 673-680 (2000).
44. Fogarty S, Hardie DG. C-terminal phosphorylation of LKB1 is not required for regulation of AMP-activated protein kinase, BRSK1, BRSK2, or cell cycle arrest. J. Biol. Chem. 284, 77-84 (2009).
45. Lan F, Cacicedo JM, Ruderman N, Ido Y. SIRT1 modulation of the acetylation status, cytosolic localization, and activity of LKB1. Possible role in AMP-activated protein kinase activation. J. Biol. Chem. 283, 27628-27635 (2008).
46. Xie Z, Dong Y, Zhang J, Scholz R, Neumann D, Zou MH. Identification of the serine 307 of LKB1 as a novel phosphorylation site essential for its nucleocytoplasmic transport and endothelial cell angiogenesis. Mol. Cell. Biol. 29, 3582-3596 (2009).
47. Yamada E, Pessin JE, Kurland IJ, Schwartz GJ, Bastie CC. Fyn-dependent regulation of energy expenditure and body weight is mediated by tyrosine phosphorylation of LKB1. Cell Metab. 11, 113-124 (2010). nn Study demonstrating that Fyn kinase phosphorylates LKB1 and regulates LKB1 subcellular localization.
48. Ruderman NB, Park H, Kaushik VK et al. AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise. Acta Physiol. Scand. 178, 435-442 (2003).
49. Mu J, Brozinick JT Jr, Valladares O, Bucan M, Birnbaum MJ. A role for AMP-activated protein kinase in contraction- and hypoxia-regulated glucose transport in skeletal muscle. Mol. Cell 7, 1085-1094 (2001).
50. Kurth-Kraczek EJ, Hirshman MF, Goodyear LJ, Winder WW. 5' AMPactivated protein kinase activation causes GLUT4 translocation in skeletal muscle. Diabetes 48, 1667-1671 (1999).
51. Bergeron R, Russell RR III, Young LH et al. Effect of AMPK activation on muscle glucose metabolism in conscious rats. Am. J. Physiol. 276, E938-944 (1999).
52. Jorgensen SB, Viollet B, Andreelli F et al. Knockout of the α2 but not α1 5'-AMPactivated protein kinase isoform abolishes 5-aminoimidazole-4-carboxamide-1-β-4- ribofuranosidebut not contraction-induced glucose uptake in skeletal muscle. J. Biol. Chem. 279, 1070-1079 (2004).
53. Villena JA, Viollet B, Andreelli F, Kahn A, Vaulont S, Sul HS. Induced adiposity and adipocyte hypertrophy in mice lacking the AMP-activated protein kinase-α2 subunit. Diabetes 53, 2242-2249 (2004).
54. Viollet B, Andreelli F, Jorgensen SB et al. The AMP-activated protein kinase α2 catalytic subunit controls whole-body insulin sensitivity. J. Clin. Invest. 111, 91-98 (2003).
55. Dzamko N, van Denderen BJ, Hevener AL et al. AMPK β1 deletion reduces appetite, preventing obesity and hepatic insulin resistance. J. Biol. Chem. 285, 115-122
56. Steinberg GR, O'Neill HM, Dzamko NL et al. Whole-body deletion of AMPK {β}2 reduces muscle AMPK and exercise capacity. J. Biol. Chem.
57. Fujii N, Hirshman MF, Kane EM et al. AMP-activated protein kinase α2 activity is not essential for contraction- and hyperosmolarity-induced glucose transport in skeletal muscle. J. Biol. Chem. 280, 39033-39041 (2005).
58. Egan B, Zierath JR. Hunting for the SNARK in metabolic disease. Am. J. Physiol. Endocrinol. Metab. 296, E969-972 (2009).
59. Koh HJ, Toyoda T, Fujii N et al. Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle. Proc. Natl Acad. Sci. USA 107, 15541-15546
60. Tsuchihara K, Ogura T, Fujioka R et al. Susceptibility of Snark-deficient mice to azoxymethane-induced colorectal tumorigenesis and the formation of aberrant crypt foci. Cancer Sci. 99, 677-682 (2008).
61. Lochhead PA, Salt IP, Walker KS, Hardie DG, Sutherland C. 5-aminoimidazole-4-carboxamide riboside mimics the effects of insulin on the expression of the 2 key gluconeogenic genes PEPCK and glucose-6-phosphatase. Diabetes 49, 896-903 (2000).
62. Viana AY, Sakoda H, Anai M et al. Role of hepatic AMPK activation in glucose metabolism and dexamethasone-induced regulation of AMPK expression. Diabetes Res. Clin. Pract. 73, 135-142 (2006).
63. Foretz M, Ancellin N, Andreelli F et al. Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes 54, 1331-1339 (2005).
64. Koo SH, Flechner L, Qi L et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437, 1109-1111 (2005).
65. Merrill GF, Kurth EJ, Hardie DG, Winder WW. AICA riboside increases AMPactivated protein kinase, fatty acid oxidation and glucose uptake in rat muscle. Am. J. Physiol. 273, E1107-1112 (1997).
66. Assifi MM, Suchankova G, Constant S, Prentki M, Saha AK, Ruderman NB. AMP-activated protein kinase and coordination of hepatic fatty acid metabolism of starved/carbohydrate-refed rats. Am. J. Physiol. Endocrinol. Metab. 289, E794-800 (2005).
67. Samuel VT, Petersen KF, Shulman GI. Lipid-induced insulin resistance: Unravelling the mechanism. Lancet 375, 2267-2277
68. Saddik M, Gamble J, Witters LA, Lopaschuk GD. Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J. Biol. Chem. 268, 25836-25845 (1993).
69. McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur. J. Biochem. 244, 1-14 (1997).
70. Cook GA, Gamble MS. Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. J. Biol. Chem. 262, 2050-2055 (1987).
71. Leclerc I, Kahn A, Doiron B. The 5'-AMPactivated protein kinase inhibits the transcriptional stimulation by glucose in liver cells, acting through the glucose response complex. FEBS Lett. 431, 180-184 (1998).
72. Foretz M, Carling D, Guichard C, Ferre P, Foufelle F. AMP-activated protein kinase inhibits the glucose-activated expression of fatty acid synthase gene in rat hepatocytes. J. Biol. Chem. 273, 14767-14771 (1998).
73. Lee WJ, Kim M, Park HS et al. AMPK activation increases fatty acid oxidation in skeletal muscle by activating PPARa and PGC-1. Biochem. Biophys. Res. Commun. 340, 291-295 (2006).
74. Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7, 941-946 (2001).
75. Minokoshi Y, Kim YB, Peroni OD et al. Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase. Nature 415, 339-343 (2002).
76. Kamohara S, Burcelin R, Halaas JL, Friedman JM, Charron MJ. Acute stimulation of glucose metabolism in mice by leptin treatment. Nature 389, 374-377 (1997).
77. Steinberg GR, Rush JW, Dyck DJ. AMPK expression and phosphorylation are increased in rodent muscle after chronic leptin treatment. Am. J. Physiol. Endocrinol. Metab. 284, E648-654 (2003).
78. Minokoshi Y, Haque MS, Shimazu T. Microinjection of leptin into the ventromedial hypothalamus increases glucose uptake in peripheral tissues in rats. Diabetes 48, 287-291 (1999).
79. El-Assaad W, Buteau J, Peyot ML et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic b-cell death. Endocrinology 144, 4154-4163 (2003).
80. Kefas BA, Cai Y, Ling Z et al. AMPactivated protein kinase can induce apoptosis of insulin-producing MIN6 cells through stimulation of c-Jun-N-terminal kinase. J. Mol. Endocrinol. 30, 151-161 (2003).
81. Kefas BA, Heimberg H, Vaulont S et al. AICA-riboside induces apoptosis of pancreatic β cells through stimulation of AMP-activated protein kinase. Diabetologia 46, 250-254 (2003). (Pubitemid 36343889)
82. Cai Y, Martens GA, Hinke SA, Heimberg H, Pipeleers D, Van de Casteele M. Increased oxygen radical formation and mitochondrial dysfunction mediate b cell apoptosis under conditions of AMP-activated protein kinase stimulation. Free Radic. Biol. Med. 42, 64-78 (2007).
83. Riboulet-Chavey A, Diraison F, Siew LK, Wong FS, Rutter GA. Inhibition of AMPactivated protein kinase protects pancreatic b-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes 57, 415-423 (2008).
84. da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA. Role for AMP-activated protein kinase in glucosestimulated insulin secretion and preproinsulin gene expression. Biochem. J. 371, 761-774 (2003).
85. Gleason CE, Lu D, Witters LA, Newgard CB, Birnbaum MJ. The role of AMPK and mTOR in nutrient sensing in pancreatic b-cells. J. Biol. Chem. 282, 10341-10351 (2007).
86. Pold R, Jensen LS, Jessen N et al. Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes 54, 928-934 (2005).
87. Turnley AM, Stapleton D, Mann RJ, Witters LA, Kemp BE, Bartlett PF. Cellular distribution and developmental expression of AMP-activated protein kinase isoforms in mouse central nervous system. J. Neurochem. 72, 1707-1716 (1999).
88. Minokoshi Y, Alquier T, Furukawa N et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature 428, 569-574 (2004).
89. Lee K, Li B, Xi X, Suh Y, Martin RJ. Role of neuronal energy status in the regulation of adenosine 5'-monophosphate-activated protein kinase, orexigenic neuropeptides expression, and feeding behavior. Endocrinology 146, 3-10 (2005).
90. Chau-Van C, Gamba M, Salvi R, Gaillard RC, Pralong FP. Metformin inhibits adenosine 5'-monophosphate-activated kinase activation and prevents increases in neuropeptide Y expression in cultured hypothalamic neurons. Endocrinology 148, 507-511 (2007).
91. Kim MS, Park JY, Namkoong C et al. Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat. Med. 10, 727-733 (2004).
92. Martin TL, Alquier T, Asakura K, Furukawa N, Preitner F, Kahn BB. Dietinduced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J. Biol. Chem. 281, 18933-18941 (2006).
93. Andersson U, Filipsson K, Abbott CR et al. AMP-activated protein kinase plays a role in the control of food intake. J. Biol. Chem. 279, 12005-12008 (2004).
94. Claret M, Smith MA, Batterham RL et al. AMPK is essential for energy homeostasis regulation and glucose sensing by POMC and AgRP neurons. J. Clin. Invest. 117, 2325-2336 (2007).
95. Mountjoy PD, Bailey SJ, Rutter GA. Inhibition by glucose or leptin of hypothalamic neurons expressing neuropeptide Y requires changes in AMP-activated protein kinase activity. Diabetologia 50, 168-177 (2007).
96. Kola B, Hubina E, Tucci SA et al. Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J. Biol. Chem. 280, 25196-25201 (2005).
97. Tomas E, Tsao TS, Saha AK et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: Acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc. Natl Acad. Sci. USA 99, 16309-16313 (2002).
98. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368, 1096-1105 (2006).
99. Musi N, Hirshman MF, Nygren J et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with Type 2 diabetes. Diabetes 51, 2074-2081 (2002).
100. Goodarzi MO, Bryer-Ash M. Metformin revisited: Re-evaluation of its properties and role in the pharmacopoeia of modern antidiabetic agents. Diabetes Obes. Metab. 7, 654-665 (2005).
101. Shaw RJ, Lamia KA, Vasquez D et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310, 1642-1646 (2005).
102. He L, Sabet A, Djedjos S et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 137, 635-646 (2009).
103. Foretz M, Hebrard S, Leclerc J et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355-2369 nn Study demonstrating that the glucoselowering effects of metformin are not mediated by AMPK.
104. Bastie CC, Zong H, Xu J et al. Integrative metabolic regulation of peripheral tissue fatty acid oxidation by the SRC kinase family member Fyn. Cell Metab. 5, 371-381 (2007). n Study demonstrating that the Fyn kinases play an important role in lipid metabolism.
105. Saito YD, Jensen AR, Salgia R, Posadas EM. Fyn: A novel molecular target in cancer. Cancer 116, 1629-1637 (2010).
106. Sperber BR, Boyle-Walsh EA, Engleka MJ et al. A unique role for Fyn in CNS myelination. J. Neurosci. 21, 2039-2047 (2001).
107. Engen JR, Wales TE, Hochrein JM et al. Structure and dynamic regulation of Src-family kinases. Cell Mol. Life Sci. 65, 3058-3073 (2008).
108. Picard C, Gilles A, Pontarotti P, Olive D, Collette Y. Cutting edge: Recruitment of the ancestral fyn gene during emergence of the adaptive immune system. J. Immunol. 168, 2595-2598 (2002).
109. Salmond RJ, Filby A, Qureshi I, Caserta S, Zamoyska R. T-cell receptor proximal signaling via the Src-family kinases, Lck and Fyn, influences T-cell activation, differentiation, and tolerance. Immunol. Rev. 228, 9-22 (2009).
110. Sefton BM, Taddie JA. Role of tyrosine kinases in lymphocyte activation. Curr. Opin. Immunol. 6, 372-379 (1994).
111. Takeuchi M, Kuramochi S, Fusaki N et al. Functional and physical interaction of protein-tyrosine kinases Fyn and Csk in the T-cell signaling system. J. Biol. Chem. 268, 27413-27419 (1993).
112. Palacios EH, Weiss A. Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation. Oncogene 23, 7990-8000 (2004).
113. Alland L, Peseckis SM, Atherton RE, Berthiaume L, Resh MD. Dual myristylation and palmitylation of Src family member p59fyn affects subcellular localization. J. Biol. Chem. 269, 16701-16705 (1994).
114. Mastick CC, Saltiel AR. Insulin-stimulated tyrosine phosphorylation of caveolin is specific for the differentiated adipocyte phenotype in 3T3-L1 cells. J. Biol. Chem. 272, 20706-20714 (1997).
115. Liu J, Deyoung SM, Zhang M, Dold LH, Saltiel AR. The stomatin/prohibitin/ flotillin/HflK/C domain of flotillin-1 contains distinct sequences that direct plasma membrane localization and protein interactions in 3T3-L1 adipocytes. J. Biol. Chem. 280, 16125-16134 (2005).
116. Bull HA, Brickell PM, Dowd PM. Src-related protein tyrosine kinases are physically associated with the surface antigen CD36 in human dermal microvascular endothelial cells. FEBS Lett. 351, 41-44 (1994).
117. Hunter S, Burton EA, Wu SC, Anderson SM. Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase. J. Biol. Chem. 274, 2097-2106 (1999).
118. Sun XJ, Pons S, Asano T, Myers MG Jr, Glasheen E, White MF. The fyn tyrosine kinase binds Irs-1 and forms a distinct signaling complex during insulin stimulation. J. Biol. Chem. 271, 10583-10587 (1996).
119. Christofk HR, Vander Heiden MG, Wu N, Asara JM, Cantley LC. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature 452, 181-186 (2008).
120. Sun Y, Ma YC, Huang J, Chen KY, McGarrigle DK, Huang XY. Requirement of SRC-family tyrosine kinases in fat accumulation. Biochemistry 44, 14455-14462 (2005).
121. Cooke MP, Perlmutter RM. Expression of a novel form of the fyn proto-oncogene in hematopoietic cells. New Biol. 1, 66-74 (1989).
122. Goldsmith JF, Hall CG, Atkinson TP. Identification of an alternatively spliced isoform of the fyn tyrosine kinase. Biochem. Biophys. Res. Commun. 298, 501-504 (2002).
123. Sudol M, Greulich H, Newman L, Sarkar A, Sukegawa J, Yamamoto T. A novel yes-related kinase, Yrk, is expressed at elevated levels in neural and hematopoietic tissues. Oncogene 8, 823-831 (1993).